Skip to main content
. Author manuscript; available in PMC: 2011 Aug 1.
Published in final edited form as: Ann Rheum Dis. 2011 May 17;70(8):1401–1406. doi: 10.1136/ard.2010.146365

Figure 2.

Figure 2

Adjusted* HR of hospitalised infection for biological-free, switcher and combined cohorts, compared with infliximab. *Adjusted for quintile of the infection risk score, described in the supplementary appendix (available online only).